Oculis Holding AG (NASDAQ:OCS - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $15.95, but opened at $15.60. Oculis shares last traded at $15.70, with a volume of 3,088 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Oculis in a research report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $29.20.
View Our Latest Stock Report on Oculis
Oculis Stock Down 0.9 %
The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $639.96 million, a P/E ratio of -8.90 and a beta of 0.30. The stock's 50-day simple moving average is $12.89 and its 200-day simple moving average is $12.20.
Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.13). Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.28 million. As a group, research analysts predict that Oculis Holding AG will post -2.19 earnings per share for the current fiscal year.
Oculis Company Profile
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Read More
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
